Wu Tong, Wang Xiaoli, Shen Ziyun, Zhang Zhongwei, Liu Yuhao, Fang Rong, Wang Qian, Wang Sheng, Zhou Quanhong, Qu Hongping, Dai Yunqi, Tan Ruoming
Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Ruijin 2nd Road 197, Shanghai, 200025, China.
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Antimicrob Resist Infect Control. 2024 Dec 18;13(1):150. doi: 10.1186/s13756-024-01509-y.
Recognition of carbapenem-resistant gram-negative bacteria (CR-GNB) carriage is frequently delayed, which increases the risk of subsequent infection and transmission. Previously, we developed a scoring system to identify CR-GNB carriage upon intensive care unit (ICU) admission. Although the ICU-CARB score showed satisfactory performance, it has not been externally validated. In this study, therefore, we externally validated the ICU-CARB score.
In the previous article, we introduced a risk-scoring system that incorporated seven key variables: neurological disease, high-risk department history, length of stay ≥ 14 days, ICU history, invasive mechanical ventilation, gastrointestinal tube placement, and carbapenem usage. To externally validate the ICU-CARB score, we conducted a study involving patients admitted to the ICUs of four tertiary hospitals between January 2021 and December 2023. Patients from three hospitals were grouped into Cohort I (n = 815) and those from the fourth hospital into Cohort II (n = 1602). Model calibration, discrimination, and performance were then assessed.
A total of 2417 patients were included, among which 289 (12%) carried CR-GNB upon ICU admission. Neurological disease, high-risk department history and length of stay ≥ 14 days were still 3 most important contributing factors in the scoring system. The ICU-CARB score exhibited high calibration, with an area under the receiver operating characteristic curve of 0.825 (95% confidence interval [CI], 0.778-0.873) for Cohort I and 0.823 (95% CI, 0.791-0.855) for Cohort II. The ICU-CARB score showed a highly positive association with CR-GNB carriage in both cohort I (C = 0.315; P < 0.001) and Cohort II (C = 0.381; P < 0.001).
Despite differences in patient population characteristics, the ICU-CARB score for CR-GNB carriage upon ICU admission exhibited good discrimination in external validation, supporting its potential generalizability to other ICU settings.
耐碳青霉烯类革兰氏阴性菌(CR-GNB)携带的识别常常延迟,这增加了后续感染和传播的风险。此前,我们开发了一种评分系统,用于在重症监护病房(ICU)入院时识别CR-GNB携带情况。尽管ICU-CARB评分表现令人满意,但尚未进行外部验证。因此,在本研究中,我们对ICU-CARB评分进行了外部验证。
在上一篇文章中,我们介绍了一种风险评分系统,该系统纳入了七个关键变量:神经系统疾病、高危科室病史、住院时间≥14天、ICU病史、有创机械通气、放置胃肠管和使用碳青霉烯类药物。为了对ICU-CARB评分进行外部验证,我们开展了一项研究,纳入了2021年1月至2023年12月期间入住四家三级医院ICU的患者。来自三家医院的患者被分为队列I(n = 815),来自第四家医院的患者被分为队列II(n = 1602)。然后评估模型的校准、区分度和性能。
共纳入2417例患者,其中289例(12%)在ICU入院时携带CR-GNB。神经系统疾病、高危科室病史和住院时间≥14天仍然是评分系统中最重要的3个影响因素。ICU-CARB评分显示出高度校准,队列I的受试者工作特征曲线下面积为0.825(95%置信区间[CI],0.778 - 0.873),队列II为0.823(95%CI,0.791 - 0.855)。ICU-CARB评分在队列I(C = 0.315;P < 0.001)和队列II(C = 0.381;P < 0.001)中均与CR-GNB携带呈高度正相关。
尽管患者群体特征存在差异,但ICU-CARB评分在ICU入院时对CR-GNB携带情况的外部验证中表现出良好的区分度,支持其在其他ICU环境中的潜在通用性。